Intra-Cellular Therapies, Inc. (ITCI) EPS Estimated At $-0.51; Icf International (ICFI) Sellers Decreased By 12.85% Their Shorts

February 17, 2018 - By Clifton Ray

Analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report $-0.51 EPS on March, 7.They anticipate $0.13 EPS change or 20.31% from last quarter’s $-0.64 EPS. After having $-0.53 EPS previously, Intra-Cellular Therapies, Inc.’s analysts see -3.77% EPS growth. The stock decreased 0.15% or $0.03 during the last trading session, reaching $19.97. About 486,573 shares traded or 9.61% up from the average. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 17, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Icf International Incorporated (NASDAQ:ICFI) had a decrease of 12.85% in short interest. ICFI’s SI was 157,400 shares in February as released by FINRA. Its down 12.85% from 180,600 shares previously. With 91,000 avg volume, 2 days are for Icf International Incorporated (NASDAQ:ICFI)’s short sellers to cover ICFI’s short positions. The SI to Icf International Incorporated’s float is 0.86%. The stock decreased 1.07% or $0.6 during the last trading session, reaching $55.5. About 79,063 shares traded. ICF International, Inc. (NASDAQ:ICFI) has risen 21.79% since February 17, 2017 and is uptrending. It has outperformed by 5.09% the S&P500.




ICF International, Inc. provides management, technology, and policy consulting and implementation services to government and commercial clients in the United States and internationally. The company has market cap of $1.04 billion. The firm researches, collects, and analyses critical policy, industry, and stakeholder issues, trends, and behaviors; provides assessment and advisory services on how to navigate societal, market, business, communication, and technology challenges; and designs, develops, and manages plans, frameworks, programs, and tools that are principal to its clientsÂ’ business performance. It has a 22.11 P/E ratio. It also identifies, defines, and implements technology systems and business tools through a range of standard and customized methodologies designed to match its clientsÂ’ business context; and informs and engages its clientsÂ’ constituents, customers, and employees through public relations, branding and marketing, multichannel and strategic communications, and enterprise training and communications programs.

Since September 1, 2017, it had 0 insider buys, and 7 insider sales for $2.68 million activity. 13,086 shares were sold by Wasson John, worth $654,300 on Friday, September 1. Shares for $292,968 were sold by Glover Ellen on Wednesday, September 20. Another trade for 10,000 shares valued at $515,000 was made by Morgan James C M on Friday, September 1.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.10, from 1.03 in 2017Q2. It is positive, as 17 investors sold ICF International, Inc. shares while 47 reduced holdings. 25 funds opened positions while 47 raised stakes. 16.56 million shares or 0.00% less from 16.56 million shares in 2017Q2 were reported. Ftb invested in 0% or 225 shares. Moreover, Seizert Cap Partners Lc has 0.11% invested in ICF International, Inc. (NASDAQ:ICFI). Aqr Limited Liability holds 0.01% of its portfolio in ICF International, Inc. (NASDAQ:ICFI) for 147,751 shares. 8 are held by Qs Ltd. Royal Retail Bank Of Canada has 0% invested in ICF International, Inc. (NASDAQ:ICFI) for 1,781 shares. Panagora Asset Management has 103,810 shares for 0.02% of their portfolio. Barclays Plc holds 0% of its portfolio in ICF International, Inc. (NASDAQ:ICFI) for 20,399 shares. Zebra Cap Mngmt Limited Liability Company reported 22,410 shares stake. Bridgeway Management has invested 0.04% of its portfolio in ICF International, Inc. (NASDAQ:ICFI). Great West Life Assurance Com Can accumulated 1,404 shares. Citadel Limited Liability Company holds 0% of its portfolio in ICF International, Inc. (NASDAQ:ICFI) for 9,804 shares. Blair William And Com Il has 0% invested in ICF International, Inc. (NASDAQ:ICFI) for 11,623 shares. Citigroup invested in 4,912 shares or 0% of the stock. Axa holds 0.01% of its portfolio in ICF International, Inc. (NASDAQ:ICFI) for 28,960 shares. California State Teachers Retirement System holds 0% of its portfolio in ICF International, Inc. (NASDAQ:ICFI) for 28,701 shares.

Among 7 analysts covering ICF International (NASDAQ:ICFI), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. ICF International had 9 analyst reports since July 31, 2015 according to SRatingsIntel. SunTrust maintained ICF International, Inc. (NASDAQ:ICFI) on Friday, November 3 with “Buy” rating. The firm has “Market Perform” rating given on Wednesday, December 14 by William Blair. Loop Capital initiated the shares of ICFI in report on Tuesday, January 10 with “Buy” rating. The stock has “Buy” rating by Stifel Nicolaus on Friday, July 31. As per Wednesday, October 25, the company rating was maintained by Wells Fargo. On Thursday, August 3 the stock rating was maintained by Noble Financial with “Hold”. Noble Financial maintained the shares of ICFI in report on Monday, November 6 with “Hold” rating. The rating was initiated by Barrington on Friday, January 29 with “Market Perform”.

Since September 29, 2017, it had 3 insider purchases, and 9 selling transactions for $10.92 million activity. $17,394 worth of stock was sold by Davis Robert E on Wednesday, January 3. Mates Sharon also sold $192,270 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares. Alafi Christopher D also bought $4.00 million worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Friday, September 29. ALAFI CAPITAL CO LLC had bought 258,065 shares worth $4.00M on Monday, October 2. $13,479 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was sold by Vanover Kimberly E.. LERNER RICHARD A had sold 7,000 shares worth $105,630 on Monday, December 11. $459,765 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares were sold by Halstead Michael.

Investors sentiment increased to 2.77 in 2017 Q3. Its up 1.91, from 0.86 in 2017Q2. It increased, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported. State Street invested in 737,763 shares. Quantbot Technologies L P invested in 8,614 shares. Bb Biotech Ag reported 2.20M shares or 0.96% of all its holdings. 32,176 were accumulated by Trexquant Inv L P. Bnp Paribas Arbitrage Sa stated it has 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). State Board Of Administration Of Florida Retirement Sys stated it has 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Art Advsrs Limited Co invested 0.11% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Fred Alger Mgmt Incorporated stated it has 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). First Midwest National Bank Trust Division invested in 184,836 shares or 0.36% of the stock. Us National Bank De reported 1,944 shares or 0% of all its holdings. Rhenman And Prtnrs Asset Mngmt Ab stated it has 2.38% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Samlyn Cap Limited Liability Corporation reported 0.3% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Credit Suisse Ag reported 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). First Mercantile Communications holds 0.03% or 8,791 shares in its portfolio. Perceptive Ltd has 0.56% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 929,460 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: